The Pediatric Infectious Disease Journal · 2009 · 40 citations · 8 references
PharmacyPediatricsPharmacotherapyPediatric Clinical PharmacologyPediatric ImmunologyPediatric PharmacotherapyPediatric Adverse Drug ReactionsPediatric Clinical TrialsPediatric Patient SafetyPediatric PharmacologyPediatric SafetyAdverse Drug EventsDrug DiscontinuationDrug Safety In InfantsMedication-related Adverse EventsPediatric Adverse Drug Event ReportingRegistrationTreatment Discontinuation Rates
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
8
George K. Abruzzo, Amy Flattery, Christopher Gill et al. · Antimicrobial Agents and Chemotherapy · 1997 · 245 citations · Full text
Medicine, Microbiology, Pharmacology +17